Global Ganja Report

Among the multiple grim challenges facing humanity at this moment is the specter of "antibiotic apocalypse"—so-called "superbugs" developing resistance to common antibiotics, portending a plague of incurable infections. Research in Australia now reveals anti-bacterial properties in CBD, effective even against the growing ranks of resistant superbugs. Many in the stateside cannabis industry say the development is further evidence that legal barriers to research need to come down—and fast.

The US Surgeon General has launched a new campaign hyping the supposed dangers of cannabis—a further disappointment for activists who held out hope that Trump harbored libertarian instincts and would legalize. All too predictably, the anti-legalization assumptions behind the new campaign are amply refuted by actual research.

The US Department of Agriculture is opening an Industrial Hemp Germplasm Repository, in conjunction with upstate New York's Cornell University. The facility is envisioned as a major hub for genetic analysis and research, helping to spur the hemp industry's growth regionally and nationally.

With industry waiting on the FDA to issue regs for CBD products, the agency instead released a statement explaining why it has not yet done so—including fears that the trendy cannabinoid may cause liver damage. But advocates charge that the claim is based on faulty research.

Inauguration of a global hemp research lab has been announced at Oregon State University, where a multidisciplinary team will be working to establish standards for the worldwide industry.

A Louisiana coroner declared a local woman's death to be the first on record attributed to a cannabis overdose, winning lurid national headlines. But medical experts and even federal officials as well as advocates are skeptical of the claim.

There is a growing consensus among hemp advocates that the 0.3% limit for THC content is arbitrary and is holding back the industry. And the man widely credited with arriving at this limit himself agrees.

The Contested Border
"It seems like it is pretty much pulled out of air. We ought to be looking to science to determine an appropriate threshold, determine the level at which cannabis is psychoactive and make that the standard."

This typical view is offered by attorney Patrick Goggin of Hoban Law Group, the international firm specializing in cannabis. Goggin is one of the industry's legal heavy-hitters, and has particular experience in the question of the contested border between hemp and marijuana.

Yet again, a scientific study linking cannabis use to psychiatric maladies gets widespread and sensationalistic media play. And once again, the assumptions behind the study are questionable, and the findings are further distorted by irresponsible reportage.

Does daily cannabis use, especially of high-potency "skunk" strains, lead to an increased risk of developing psychosis? Based on recent media coverage, you can be forgiven for thinking so. But you should really take a closer look before you believe the hype.